An oncology expert explains how clinical and non-clinical evidence impact the clinical pathway decision-making for patients with NSCLC.
Edward Arrowsmith, MD: We have a couple ways that we're tracking use of the pathways, and that's something we feel is critical. What we hope, both now and increasingly over time, will differentiate our pathways program. We're really striving to use real-time data to follow pathway adherence. At OneOncology, we have a robust program we call One Analytics that pulls information from a variety of sources and then allows clinicians and other practice leaders to better manage the patient care experience. We're able to follow how patients do and how providers are doing in adhering to the pathways. Something we're really excited about is a tool called Flatiron Assist. Flatiron Health is the maker of OncoEMR, which is our EMR vendor across OneOncology. This is a point-of-care tool that guides clinicians as they’re ordering treatment for non-small cell lung cancer and other cancers, that uses clinical inputs to suggest the kind of optimal- or pathway-based treatment to prescribe right at the point of care.
Non-small cell lung cancer, in some ways, has almost bifurcated in how we analyzed data. There's an increasing group of patients who, particularly talking here in stage 4 or advanced disease, have a specific target with EGFR mutant or ALK rearranged lung cancer as being the first examples of this. Increasingly, [there are] other targets, such as—[as of] a little less than a year ago—the KRAS G12C mutation. For those patients, sometimes we see dramatic results of phase 2 trials in highly targeted patient populations. In those groups, based on that phase 2 data, we and the lung cancer community as a whole integrate those treatments. Those are generally new compounds getting FDA approvals for that specific indication. Sotorasib for second-line therapy of KRAS G12C-mutated non-small cell lung cancer would be a good example of that. The other is the more common group that we're treating with chemotherapy, with immunotherapy or chemotherapy and radiation followed by immunotherapy. There, we're looking at overall survival as the primary endpoint, that we're looking to update our pathways and change our treatment algorithms.
There's a stepwise approach to the development of a pathway. The first is efficacy. The most effective treatment that helps patients live longer and better is going to be the key driving metric in pathway formation. If there are 2 treatments of equal efficacy or we think are likely to have equal efficacy, if they have not been compared head-to-head, look at the adverse event profile and go with a treatment that is likely to be easier on patients from an adverse event perspective. The third criteria if efficacy and adverse events appear is to look at value. Is a lower cost agent? Is it an agent where there are much better patient assistance programs, so for those patients who are uninsured or underinsured, there's value? It's that order of efficacy, safety, and then value when we think about agents. With things like biosimilars or generics, there is a clear example where value becomes paramount.
This transcript has been edited for clarity.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More